The CDC reported that in 2021, 93% of all young adults newly diagnosed with HIV were college-aged individuals of 18 to 24 years old. Pre-exposure prophylaxis, or PrEP, is a type of medication FDA-approved to help reduce the risk of HIV transmission; however, about 23% of people who could have benefited from PrEP were ever prescribed PrEP in 2019. This study aims to uncover what barriers to accessing PrEP that young adults in college may be facing.
Thank you for your interest, but this study is not currently enrolling.
North Carolina (Statewide)
Laura Rhodes
UNC Eshelman School of Pharmacy-Division of Practice Advancement and Clinical Education
Behavioral or Social
Observational
HIV/AIDS
LGBTQIA+
Sexual and/or Reproductive Health
UNC Students (undergrad, grad, professional)
23-2659
Copyright © 2013-2022 The NC TraCS Institute, the integrated home of the NIH Clinical and Translational Science Awards (CTSA) Program at UNC-CH. This website is made possible by CTSA Grant UL1TR002489 and the National Center for Advancing Translational Sciences.
Questions?
